Conduit Pharmaceuticals (FRA:ZK70) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals ROE % Adjusted to Book Value?

Conduit Pharmaceuticals's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Conduit Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Conduit Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Conduit Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Conduit Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals ROE % Adjusted to Book Value Chart

Conduit Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Conduit Pharmaceuticals Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial						Negative Equity	Negative Equity	-	-	-

Competitive Comparison of Conduit Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Conduit Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Conduit Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Conduit Pharmaceuticals ROE % Adjusted to Book Value Calculation

Conduit Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Conduit Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Conduit Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK70) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CDT:USA

Address

4995 Murphy Canyon Road, Suite 300, San Diego, CA, USA, 92123

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines